Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial

Kiminori Kimura, Akemi Ikoma, Maki Shibakawa, Shinji Shimoda, Kenichi Harada, Masanao Saio, Jun Imamura, Yosuke Osawa, Masamichi Kimura, Koji Nishikawa, Takuji Okusaka, Satoshi Morita, Kazuaki Inoue, Tatsuya Kanto, Koji Todaka, Yoichi Nakanishi, Michinori Kohara, Masashi Mizokami

研究成果: ジャーナルへの寄稿記事

11 引用 (Scopus)

抄録

Background There is currently no anti-fibrotic drug therapy available to treat hepatitis C virus (HCV) cirrhosis. The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator of Wnt signaling, in patients with HCV cirrhosis. Methods In this single-center, open-label, phase 1 trial, we sequentially enrolled patients with HCV cirrhosis who were classified as Child-Pugh (CP) class A or B. PRI-724 was administered as a continuous intravenous infusion of 10, 40, or 160 mg/m2/day for six cycles of 1 week on and 1 week off. The primary endpoints were frequency and severity of adverse events. The secondary endpoint was efficacy of PRI-724 in treating cirrhosis based on CP score and liver biopsy. This study is registered with ClinicalTrials.gov (no. NCT02195440). Findings Between Sept 3, 2014 and May 2, 2016, 14 patients were enrolled: CP class A:B, 6:8; median age, 62 (range: 43 to 74) years; male:female, 10:4. Twelve of the 14 patients completed six cycles of treatment; one was withdrawn from the study due to possible study drug-related liver injury (grade 3) in the 160 mg/m2/day dose cohort and one withdrew for personal reasons. Serious adverse events occurred in three patients [21% (3/14)], one of which was possibly related to PRI-724. The most common adverse events were nausea [29% (4/14)] and fatigue [21% (3/14)]. After PRI-724 administration, the CP scores worsened by 1 point in two patients in the 10 mg/m2/day cohort, improved in three patients at 1, 1, and 2 points in the 40 mg/m2/day cohort, and improved in one patient by 3 points in the 160 mg/m2/day cohort. The histology activity index scores of the liver tissue improved in two patients and exacerbated in two patients in the 10 mg/m2/day cohort, and improved in one patient in the 40 mg/m2/day cohort. Interpretation This study showed that administration of 10 or 40 mg/m2/day intravenous PRI-724 over 12 weeks was well-tolerated by patients with HCV cirrhosis; however, liver injury as a possible related serious adverse event was observed in the 160 mg/m2/day cohort. Funding Source AMED.

元の言語英語
記事番号 28844410
ページ(範囲)79-87
ページ数9
ジャーナルEBioMedicine
23
DOI
出版物ステータス出版済み - 9 2017

Fingerprint

Catenins
Viruses
Hepacivirus
Liver
Labels
Fibrosis
Safety
Molecules
Drug therapy
Histology
Biopsy
Modulators
Fatigue of materials
Tissue
Pharmaceutical Preparations
Wounds and Injuries
Intravenous Infusions
Nausea
Fatigue

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

これを引用

Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis : A Single-Center, Open-Label, Dose Escalation Phase 1 Trial. / Kimura, Kiminori; Ikoma, Akemi; Shibakawa, Maki; Shimoda, Shinji; Harada, Kenichi; Saio, Masanao; Imamura, Jun; Osawa, Yosuke; Kimura, Masamichi; Nishikawa, Koji; Okusaka, Takuji; Morita, Satoshi; Inoue, Kazuaki; Kanto, Tatsuya; Todaka, Koji; Nakanishi, Yoichi; Kohara, Michinori; Mizokami, Masashi.

:: EBioMedicine, 巻 23, 28844410, 09.2017, p. 79-87.

研究成果: ジャーナルへの寄稿記事

Kimura, K, Ikoma, A, Shibakawa, M, Shimoda, S, Harada, K, Saio, M, Imamura, J, Osawa, Y, Kimura, M, Nishikawa, K, Okusaka, T, Morita, S, Inoue, K, Kanto, T, Todaka, K, Nakanishi, Y, Kohara, M & Mizokami, M 2017, 'Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial', EBioMedicine, 巻. 23, 28844410, pp. 79-87. https://doi.org/10.1016/j.ebiom.2017.08.016
Kimura, Kiminori ; Ikoma, Akemi ; Shibakawa, Maki ; Shimoda, Shinji ; Harada, Kenichi ; Saio, Masanao ; Imamura, Jun ; Osawa, Yosuke ; Kimura, Masamichi ; Nishikawa, Koji ; Okusaka, Takuji ; Morita, Satoshi ; Inoue, Kazuaki ; Kanto, Tatsuya ; Todaka, Koji ; Nakanishi, Yoichi ; Kohara, Michinori ; Mizokami, Masashi. / Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis : A Single-Center, Open-Label, Dose Escalation Phase 1 Trial. :: EBioMedicine. 2017 ; 巻 23. pp. 79-87.
@article{e812a812f1f0495f988d2b4c742d1762,
title = "Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial",
abstract = "Background There is currently no anti-fibrotic drug therapy available to treat hepatitis C virus (HCV) cirrhosis. The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator of Wnt signaling, in patients with HCV cirrhosis. Methods In this single-center, open-label, phase 1 trial, we sequentially enrolled patients with HCV cirrhosis who were classified as Child-Pugh (CP) class A or B. PRI-724 was administered as a continuous intravenous infusion of 10, 40, or 160 mg/m2/day for six cycles of 1 week on and 1 week off. The primary endpoints were frequency and severity of adverse events. The secondary endpoint was efficacy of PRI-724 in treating cirrhosis based on CP score and liver biopsy. This study is registered with ClinicalTrials.gov (no. NCT02195440). Findings Between Sept 3, 2014 and May 2, 2016, 14 patients were enrolled: CP class A:B, 6:8; median age, 62 (range: 43 to 74) years; male:female, 10:4. Twelve of the 14 patients completed six cycles of treatment; one was withdrawn from the study due to possible study drug-related liver injury (grade 3) in the 160 mg/m2/day dose cohort and one withdrew for personal reasons. Serious adverse events occurred in three patients [21{\%} (3/14)], one of which was possibly related to PRI-724. The most common adverse events were nausea [29{\%} (4/14)] and fatigue [21{\%} (3/14)]. After PRI-724 administration, the CP scores worsened by 1 point in two patients in the 10 mg/m2/day cohort, improved in three patients at 1, 1, and 2 points in the 40 mg/m2/day cohort, and improved in one patient by 3 points in the 160 mg/m2/day cohort. The histology activity index scores of the liver tissue improved in two patients and exacerbated in two patients in the 10 mg/m2/day cohort, and improved in one patient in the 40 mg/m2/day cohort. Interpretation This study showed that administration of 10 or 40 mg/m2/day intravenous PRI-724 over 12 weeks was well-tolerated by patients with HCV cirrhosis; however, liver injury as a possible related serious adverse event was observed in the 160 mg/m2/day cohort. Funding Source AMED.",
author = "Kiminori Kimura and Akemi Ikoma and Maki Shibakawa and Shinji Shimoda and Kenichi Harada and Masanao Saio and Jun Imamura and Yosuke Osawa and Masamichi Kimura and Koji Nishikawa and Takuji Okusaka and Satoshi Morita and Kazuaki Inoue and Tatsuya Kanto and Koji Todaka and Yoichi Nakanishi and Michinori Kohara and Masashi Mizokami",
year = "2017",
month = "9",
doi = "10.1016/j.ebiom.2017.08.016",
language = "English",
volume = "23",
pages = "79--87",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis

T2 - A Single-Center, Open-Label, Dose Escalation Phase 1 Trial

AU - Kimura, Kiminori

AU - Ikoma, Akemi

AU - Shibakawa, Maki

AU - Shimoda, Shinji

AU - Harada, Kenichi

AU - Saio, Masanao

AU - Imamura, Jun

AU - Osawa, Yosuke

AU - Kimura, Masamichi

AU - Nishikawa, Koji

AU - Okusaka, Takuji

AU - Morita, Satoshi

AU - Inoue, Kazuaki

AU - Kanto, Tatsuya

AU - Todaka, Koji

AU - Nakanishi, Yoichi

AU - Kohara, Michinori

AU - Mizokami, Masashi

PY - 2017/9

Y1 - 2017/9

N2 - Background There is currently no anti-fibrotic drug therapy available to treat hepatitis C virus (HCV) cirrhosis. The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator of Wnt signaling, in patients with HCV cirrhosis. Methods In this single-center, open-label, phase 1 trial, we sequentially enrolled patients with HCV cirrhosis who were classified as Child-Pugh (CP) class A or B. PRI-724 was administered as a continuous intravenous infusion of 10, 40, or 160 mg/m2/day for six cycles of 1 week on and 1 week off. The primary endpoints were frequency and severity of adverse events. The secondary endpoint was efficacy of PRI-724 in treating cirrhosis based on CP score and liver biopsy. This study is registered with ClinicalTrials.gov (no. NCT02195440). Findings Between Sept 3, 2014 and May 2, 2016, 14 patients were enrolled: CP class A:B, 6:8; median age, 62 (range: 43 to 74) years; male:female, 10:4. Twelve of the 14 patients completed six cycles of treatment; one was withdrawn from the study due to possible study drug-related liver injury (grade 3) in the 160 mg/m2/day dose cohort and one withdrew for personal reasons. Serious adverse events occurred in three patients [21% (3/14)], one of which was possibly related to PRI-724. The most common adverse events were nausea [29% (4/14)] and fatigue [21% (3/14)]. After PRI-724 administration, the CP scores worsened by 1 point in two patients in the 10 mg/m2/day cohort, improved in three patients at 1, 1, and 2 points in the 40 mg/m2/day cohort, and improved in one patient by 3 points in the 160 mg/m2/day cohort. The histology activity index scores of the liver tissue improved in two patients and exacerbated in two patients in the 10 mg/m2/day cohort, and improved in one patient in the 40 mg/m2/day cohort. Interpretation This study showed that administration of 10 or 40 mg/m2/day intravenous PRI-724 over 12 weeks was well-tolerated by patients with HCV cirrhosis; however, liver injury as a possible related serious adverse event was observed in the 160 mg/m2/day cohort. Funding Source AMED.

AB - Background There is currently no anti-fibrotic drug therapy available to treat hepatitis C virus (HCV) cirrhosis. The aim of this study was to assess the safety, tolerability, and anti-fibrotic effect of PRI-724, a small-molecule modulator of Wnt signaling, in patients with HCV cirrhosis. Methods In this single-center, open-label, phase 1 trial, we sequentially enrolled patients with HCV cirrhosis who were classified as Child-Pugh (CP) class A or B. PRI-724 was administered as a continuous intravenous infusion of 10, 40, or 160 mg/m2/day for six cycles of 1 week on and 1 week off. The primary endpoints were frequency and severity of adverse events. The secondary endpoint was efficacy of PRI-724 in treating cirrhosis based on CP score and liver biopsy. This study is registered with ClinicalTrials.gov (no. NCT02195440). Findings Between Sept 3, 2014 and May 2, 2016, 14 patients were enrolled: CP class A:B, 6:8; median age, 62 (range: 43 to 74) years; male:female, 10:4. Twelve of the 14 patients completed six cycles of treatment; one was withdrawn from the study due to possible study drug-related liver injury (grade 3) in the 160 mg/m2/day dose cohort and one withdrew for personal reasons. Serious adverse events occurred in three patients [21% (3/14)], one of which was possibly related to PRI-724. The most common adverse events were nausea [29% (4/14)] and fatigue [21% (3/14)]. After PRI-724 administration, the CP scores worsened by 1 point in two patients in the 10 mg/m2/day cohort, improved in three patients at 1, 1, and 2 points in the 40 mg/m2/day cohort, and improved in one patient by 3 points in the 160 mg/m2/day cohort. The histology activity index scores of the liver tissue improved in two patients and exacerbated in two patients in the 10 mg/m2/day cohort, and improved in one patient in the 40 mg/m2/day cohort. Interpretation This study showed that administration of 10 or 40 mg/m2/day intravenous PRI-724 over 12 weeks was well-tolerated by patients with HCV cirrhosis; however, liver injury as a possible related serious adverse event was observed in the 160 mg/m2/day cohort. Funding Source AMED.

UR - http://www.scopus.com/inward/record.url?scp=85028059251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028059251&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2017.08.016

DO - 10.1016/j.ebiom.2017.08.016

M3 - Article

C2 - 28844410

AN - SCOPUS:85028059251

VL - 23

SP - 79

EP - 87

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

M1 - 28844410

ER -